China has tightened regulations on investigator-initiated trials, with consequences not just for Chinese researchers but some Americans, too.

China has tightened regulations on investigator-initiated trials, with consequences not just for Chinese researchers but some Americans, too.

Flawed U.S. policies threaten American biopharmaceutical leadership as China accelerates clinical trials and innovation incentives.